ClinicalTrials.gg
CompletedNCT04707768Updated Jan 15, 2025Results posted

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

A Phase 3 interventional study of Vadadustat and Mircera® in Anemia Associated With Chronic Kidney Disease (CKD), sponsored by Akebia Therapeutics. Completed at 58 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-15.

Sponsored by Akebia Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
456
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing vadadustat in Anemia — 1 open to participants now, 1 under way, none of them phase 3. vadadustat · Anemia.

Enrollment
5th of 27
456 · median 60
Started
2021
the only one that year
Phase 3
14 of 27
none open now
Registered
23rd of 27
by date
Lead sponsor
21 of 27
Akebia Therapeutics

Among the 27 studies testing vadadustat in Anemia, this one is the 5th largest by enrollment, is the only one that started in 2021, is one of 14 in phase 3, and was the 23rd registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 27 studies testing vadadustat in Anemia is open now. Recruiting first, the newest first:

About vadadustat

vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing vadadustat in Anemia, or all of them as a file.
02

Study summary

This study will be conducted to demonstrate the efficacy and safety of vadadustat administered three times weekly (TIW) compared to a long-acting erythropoiesis-stimulating agent (ESA) (Mircera®) for the maintenance treatment of anemia in hemodialysis participants.

Read the detailed description

Following randomization, there will be 2 periods during the study:

  • Conversion and Maintenance Period (Weeks 0 to 52): There will be a primary efficacy evaluation period (Weeks 20 to 26) and a secondary efficacy evaluation period (Weeks 46 to 52).
  • Safety Follow-up Period (Early Termination [ET] and Follow-Up): post-treatment safety follow-up visit (ET/End of Treatment [EOT] +4 weeks) either in person or via telephone.
03

Conditions studied

  • Anemia Associated With Chronic Kidney Disease (CKD)

Keywords

  • Anemia
  • Chronic Kidney Disease
  • CKD
  • Hemodialysis
  • Vadadustat
  • Erythropoiesis-stimulating agent (ESA)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age
  • Receiving chronic, outpatient in-center hemodialysis three times weekly (TIW) for end-stage kidney disease for at least 12 weeks prior to Screening Visit 1 (SV1)
  • Currently maintained on Mircera® (≤250 μg/month) with at least 2 doses received within 8 weeks prior to Screening Visit 2 (SV2)
  • Mean Screening (Hb) between 8.5 and 11.0 grams per deciliter (g/dL) (inclusive), as determined by the average of 2 Hb values measured by the central laboratory at least 4 days apart between SV1 and SV2
  • Serum ferritin ≥100 nanograms per milliliter (ng/mL) and transferrin saturation (TSAT) ≥20% during Screening
  • Folate and vitamin B12 measurements ≥ lower limit of normal during Screening

Exclusion criteria

Exclusion Criteria:

  • Anemia due to a cause other than chronic kidney disease (CKD).
  • bleeding event within 8 weeks prior to Baseline
  • Red blood cell (RBC) transfusion within 8 weeks prior to Baseline
  • Having received any doses of darbepoetin alfa (Aranesp®) within 4 weeks prior to Baseline
  • Having received any doses of epoetin alfa (Epogen®) within 1 week prior to Baseline.
  • Current uncontrolled hypertension.
  • Acute coronary syndrome (hospitalization for unstable angina or myocardial infarction), surgical or percutaneous intervention for coronary, cerebrovascular or peripheral artery disease (aortic or lower extremity), surgical or percutaneous valvular replacement or repair, sustained ventricular tachycardia, hospitalization for heart failure (HF) or Class IV HF, or stroke within 12 weeks prior to or during Screening.
  • Known to vadadustat, Mircera®, or any of their .
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
456 participants (actual)

Study arms

  • Experimental
    Vadadustat low dose

    Participants previously receiving Mircera® received vadadustat for up to 52 weeks with an initial dose of 600 milligrams (mg).

    Drug: Vadadustat

  • Experimental
    Vadadustat high dose

    Participants previously receiving Mircera® received vadadustat for up to 52 weeks with an initial dose of 900 mg.

    Drug: Vadadustat

  • Active comparator
    Mircera®

    Participants will continue to receive Mircera® for up to 52 weeks.

    Drug: Mircera®

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Evaluation Period (PEP) (Weeks 20 to 26)

    The Baseline Hb was defined as the average of last 2 central laboratory Hb measurements of samples taken at or prior to the first dose. The average for the PEP was calculated as the average of all Hb measurements from the central laboratory within the three visit windows during Weeks 20 through 26. Analysis was conducted using an analysis of covariance (ANCOVA) model with multiple imputation for missing data with randomization stratification factors and Baseline Hb as covariates. Change from Baseline was calculated as PEP value minus the Baseline value.

    Time frame: Baseline; Weeks 20 to 26

Secondary outcomes

  1. Change From Baseline in Hb to the Average Over the Secondary Evaluation Period (SEP) (Weeks 46 to 52)

    The Baseline Hb was defined as the average of the last 2 central laboratory Hb values taken on or prior to the first dose date. The average for the SEP was calculated as the average of all Hb measurements from the central laboratory within the three visit windows during Weeks 46 through 52. Analysis was conducted using an ANCOVA model with multiple imputation for missing data with randomization stratification factors and Baseline Hb as covariates. Change from Baseline was calculated as SEP value minus the Baseline value.

    Time frame: Baseline; Weeks 46 to 52

07

Results

Posted Jan 15, 2025

Participant flow

This was a randomzied, open-label, active-controlled study of the efficacy and safety of conversion from long-acting Erythropoiesis-stimulating Agent (ESA) (Methoxy polyethylene glycol-epoetin beta \[Mircera®\]) to vadadustat Three Times Weekly (TIW) for the maintenance treatment of anemia in hemodialysis participants.

Participant flow — Overall Study
MilestoneVadadustat 600 mg TIWVadadustat 900 mg TIWMircera®
Started152152152
Completed9998118
Not completed535434
Withdrew: Adverse event9183
Withdrew: Investigator's discretion843
Withdrew: Withdrawal by subject682
Withdrew: Lack of efficacy130
Withdrew: Lost to follow-up003
Withdrew: Death131113
Withdrew: Protocol violation210
Withdrew: Non compliance with study drug100
Withdrew: Transplant448
Withdrew: Other952

Outcome measures

PrimaryChange From Baseline in Hemoglobin (Hb) to the Average Over the Primary Evaluation Period (PEP) (Weeks 20 to 26)

The Baseline Hb was defined as the average of last 2 central laboratory Hb measurements of samples taken at or prior to the first dose. The average for the PEP was calculated as the average of all Hb measurements from the central laboratory within the three visit windows during Weeks 20 through 26. Analysis was conducted using an analysis of covariance (ANCOVA) model with multiple imputation for missing data with randomization stratification factors and Baseline Hb as covariates. Change from Baseline was calculated as PEP value minus the Baseline value.

Time frame:
Baseline; Weeks 20 to 26
Reported as:
Least squares mean · Grams per deciliter (g/dL)
Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Evaluation Period (PEP) (Weeks 20 to 26)
Grams per deciliter (g/dL)Vadadustat 600 mg TIWVadadustat 900 mg TIWMircera®
Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Evaluation Period (PEP) (Weeks 20 to 26)-0.07 ± 0.0950.14 ± 0.0950.36 ± 0.092
SecondaryChange From Baseline in Hb to the Average Over the Secondary Evaluation Period (SEP) (Weeks 46 to 52)

The Baseline Hb was defined as the average of the last 2 central laboratory Hb values taken on or prior to the first dose date. The average for the SEP was calculated as the average of all Hb measurements from the central laboratory within the three visit windows during Weeks 46 through 52. Analysis was conducted using an ANCOVA model with multiple imputation for missing data with randomization stratification factors and Baseline Hb as covariates. Change from Baseline was calculated as SEP value minus the Baseline value.

Time frame:
Baseline; Weeks 46 to 52
Reported as:
Least squares mean · Grams per deciliter
Change From Baseline in Hb to the Average Over the Secondary Evaluation Period (SEP) (Weeks 46 to 52)
Grams per deciliterVadadustat 600 mg TIWVadadustat 900 mg TIWMircera®
Change From Baseline in Hb to the Average Over the Secondary Evaluation Period (SEP) (Weeks 46 to 52)-0.11 ± 0.110-0.22 ± 0.1230.16 ± 0.102

Adverse events

Collected over Day 1 through Week 56. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vadadustat 600 mg TIW14/151 (9.3%)68/151 (45%)61/151 (40.4%)
Vadadustat 900 mg TIW12/150 (8%)66/150 (44%)67/150 (44.7%)
Mircera®17/150 (11.3%)67/150 (44.7%)64/150 (42.7%)
Most frequent serious events
Showing 10 of 197
Most frequent serious events
EventVadadustat 600 mg TIWVadadustat 900 mg TIWMircera®
Cardiac arrestCardiac disorders2/1513/15011/150
COVID 19 pneumoniaInfections and infestations1/1514/1508/150
PneumoniaInfections and infestations4/1517/1502/150
HypervolaemiaMetabolism and nutrition disorders7/1516/1504/150
COVID 19Infections and infestations3/1515/1506/150
Acute myocardial infarctionCardiac disorders4/1513/1505/150
HyperkalaemiaMetabolism and nutrition disorders4/1514/1505/150
Arteriovenous graft thrombosisInjury, poisoning and procedural complications1/1513/1505/150
Acute respiratory failureRespiratory, thoracic and mediastinal disorders4/1515/1505/150
Cardiac failure congestiveCardiac disorders5/1512/1501/150
Most frequent other events
Showing 10 of 11
Most frequent other events
EventVadadustat 600 mg TIWVadadustat 900 mg TIWMircera®
DiarrhoeaGastrointestinal disorders16/15121/15011/150
COVID 19Infections and infestations19/15118/15019/150
NauseaGastrointestinal disorders12/15113/1507/150
HyperkalaemiaMetabolism and nutrition disorders6/15113/15012/150
FallInjury, poisoning and procedural complications11/1518/15011/150
HypertensionVascular disorders5/1514/15011/150
HeadacheNervous system disorders3/15110/1505/150
DyspnoeaRespiratory, thoracic and mediastinal disorders9/1518/1504/150
Arteriovenous fistula site complicationInjury, poisoning and procedural complications7/1518/1507/150
VomitingGastrointestinal disorders4/1515/1508/150

Baseline characteristics

Randomized population included all randomized participants.

Age, Continuous
Age, Continuous(Years)Vadadustat 600 mg TIWVadadustat 900 mg TIWMircera®Total
Mean59.4 ± 14.2061.9 ± 13.2761.6 ± 12.8061.0 ± 13.45
Sex: Female, Male
Sex: Female, Male(Participants)Vadadustat 600 mg TIWVadadustat 900 mg TIWMircera®Total
Female686066194
Male849286262
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Vadadustat 600 mg TIWVadadustat 900 mg TIWMircera®Total
Hispanic or Latino424056138
Not Hispanic or Latino11010995314
Unknown or Not Reported0314
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Vadadustat 600 mg TIWVadadustat 900 mg TIWMircera®Total
American Indian or Alaska Native53412
Asian3238
Native Hawaiian or Other Pacific Islander1001
Black or African American565953168
White868792265
More than one race0000
Unknown or Not Reported1102
08

Study locations

58 sites
  • Research Site
    Huntsville, Alabama 35805, United States
  • Research Site
    Phoenix, Arizona 85035, United States
  • Research Site
    Pine Bluff, Arkansas 71603, United States
  • Research Site
    El Centro, California 92243, United States
  • Research Site
    Escondido, California 92025, United States
  • Research Site
    Fresno, California 93720, United States
  • Research Site
    Granada Hills, California 91344, United States
  • Research Site
    Porterville, California 93257, United States
  • Research Site
    San Diego, California 92111, United States
  • Research Site
    Arvada, Colorado 80002, United States
  • Research Site
    Denver, Colorado 80210, United States
  • Research Site
    Hockessin, Delaware 19707, United States
  • Research Site
    Bradenton, Florida 34209, United States
  • Research Site
    Coral Gables, Florida 33134, United States
  • Research Site#1
    Coral Springs, Florida 33071, United States
  • Research Site#2
    Coral Springs, Florida 33071, United States
  • Research Site
    Jacksonville, Florida 32216, United States
  • Research Site
    Athens, Georgia 30606, United States
  • Research Site
    Buford, Georgia 30518, United States
  • Research Site
    Dalton, Georgia 30720, United States
  • Research Site
    Macon, Georgia 31201, United States
  • Research Site
    Nampa, Idaho 83687, United States
  • Research Site
    Baton Rouge, Louisiana 70884, United States
  • Research Site
    Shreveport, Louisiana 71101, United States
  • Research Site
    Plymouth, Massachusetts 02360, United States
  • Research Site
    Springfield, Massachusetts 01107, United States
  • Research Site
    Kalamazoo, Michigan 49007, United States
  • Research Site
    Rochester Hills, Michigan 48309, United States
  • Research Site
    Saint Clair Shores, Michigan 48081, United States
  • Research Site
    Brookhaven, Mississippi 39601, United States
  • Research Site
    Columbus, Mississippi 39705, United States
  • Research Site
    Tupelo, Mississippi 38801, United States
  • Research Site
    North Platte, Nebraska 69101, United States
  • Research Site
    Las Vegas, Nevada 89115, United States
  • Research Site
    Reno, Nevada 89511, United States
  • Research Site
    Portsmouth, New Hampshire 03801, United States
  • Research Site
    Albuquerque, New Mexico 87109, United States
  • Research Site
    Gallup, New Mexico 87301, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Durham, North Carolina 27704, United States
  • Research Site
    Kinston, North Carolina 28504, United States
  • Research Site
    Raleigh, North Carolina 27609, United States
  • Research Site
    Columbus, Ohio 43215, United States
  • Research Site
    Kittanning, Pennsylvania 16201, United States
  • Research Site
    Knoxville, Tennessee 37923, United States
  • Research Site
    Arlington, Texas 76015, United States
  • Research Site
    Austin, Texas 78758, United States
  • Research Site
    Dallas, Texas 75230, United States
  • Research Site
    Dallas, Texas 75231, United States
  • Research Site
    Houston, Texas 77074, United States
  • Research Site
    Houston, Texas 77099, United States
  • Research Site
    Mansfield, Texas 76063, United States
  • Research Site
    Mission, Texas 78572, United States
  • Research Site
    San Antonio, Texas 78211, United States
  • Research Site
    San Antonio, Texas 78251, United States
  • Research Site
    Alexandria, Virginia 22304, United States
  • Research Site
    Salem, Virginia 24153, United States
  • Research Site
    Woodbridge, Virginia 22192, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Jan 2023, 18 months.

Results were first posted in Jan 2025, 2 years after primary completion. A results delay was requested in Dec 2023.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 18 months is below that.

Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2021
First posted
Jan 13, 2021
StartActual
Jun 18, 2021
Primary completionActual
Jan 6, 2023
CompletionActual
Jan 30, 2023
Results delay requested
Dec 14, 2023
Results first posted
Jan 15, 2025
Last update
Jan 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04707768
Responsible party
Sponsor
First posted
Jan 13, 2021
Start date
Jun 18, 2021
Primary completion
Jan 6, 2023
Completion
Jan 30, 2023
Results posted
Jan 15, 2025
Last update
Jan 15, 2025

Study contacts

Chief Medical Officer
study director · Akebia Therapeutics Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vadadustat

Start the discussion